Annals of neurology
-
Annals of neurology · Jul 2016
Randomized Controlled TrialRecombinant human erythropoietin improves neurological outcomes in very preterm infants.
To evaluate the efficacy and safety of repeated low-dose human recombinant erythropoietin (rhEPO) in the improvement of neurological outcomes in very preterm infants. ⋯ Repeated low-dose rhEPO treatment reduced the risk of long-term neurological disability in very preterm infants with no obvious adverse effects. Ann Neurol 2016;80:24-34.